CX11 (VCT220): The Oral GLP-1 Pill With 12% Weight Loss

The race to build a GLP-1 pill that works as well as an injection now has a candidate most Western readers have never heard of. CX11 — known as VCT220 in China — is a once-daily oral small-molecule GLP-1 receptor agonist that has already completed a pivotal Phase 3 trial in Chinese adults and posted its first U.S. Phase 2 results in July 2026. The headline numbers put it in the same tier as Eli Lilly's orforglipron, and its gastrointestinal tolerability may be its most interesting feature.

Evidence: "VCT220, a novel oral small molecule once-daily GLP-1 receptor agonist, was safe and led to robust and clinically meaningful body weight reduction and improvements in cardiac risk factors in Chinese adults with overweight or obesity." — Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity. Diabetes. 2025. DOI: 10.2337/db25-743-P

What Is CX11?

CX11 is a non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily pill. It was discovered and developed by Vincentage Pharma in China under the code VCT220. In November 2024, Corxel Pharmaceuticals (Berkeley Heights, New Jersey) acquired worldwide rights outside Greater China and renamed the program CX11. The two names refer to the same molecule at different points on the map.

The chemistry matters more than the branding. Semaglutide, tirzepatide, and liraglutide are peptides — protein fragments that stomach acid and digestive enzymes destroy on contact. That is why they are injected, and why the peptide-based oral semaglutide pill requires an absorption enhancer plus strict fasting rules to deliver a usable dose.

A small molecule sidesteps the problem entirely. CX11 is chemically synthesized, survives digestion, and absorbs without help. Corxel reports it needs no food or water restrictions and no refrigeration or light-protected storage — three practical constraints that shape daily life on current GLP-1 therapy. It shares this design with orforglipron and aleniglipron, the two better-known entrants in the oral small-molecule class.

How It Works

CX11 activates the same receptor as every drug in the class, producing the familiar chain of effects:

Appetite suppression via hypothalamic GLP-1 receptor signaling, which reduces hunger and quiets food noise
Slowed gastric emptying, extending fullness after meals
Glucose-dependent insulin secretion, improving glycemic control without driving hypoglycemia
Suppressed glucagon release, lowering fasting glucose

Because the receptor is the same, the therapeutic ceiling is set less by the target than by how much drug can be delivered and how well patients tolerate it. That is exactly where oral small molecules have historically struggled — and where CX11's data are worth reading closely.

CX11 Phase 3 Results in China

The pivotal Chinese trial (NCT06939296) is the most substantial dataset on the molecule. It randomized 840 adults with obesity (BMI ≥28 kg/m²) or overweight (BMI 24–28 kg/m²) plus at least one weight-related comorbidity, in a 1:1:1 design, to VCT220 120 mg, VCT220 160 mg, or placebo once daily for 52 weeks.

Body weight reduction at 52 weeks:

Arm	Mean weight reduction
VCT220 120 mg	−12.2%
VCT220 160 mg	−12.4%
Placebo	−1.3%

Both doses were statistically superior to placebo. The near-identical result at 120 mg and 160 mg suggests the dose–response curve flattens near the top of the tested range — useful information, since it implies most of the benefit is available at the lower dose with less drug exposure.

Vincentage has announced plans to file a New Drug Application with China's National Medical Products Administration. These are company-reported top-line results; the full trial has not yet appeared in a peer-reviewed journal, and the detailed efficacy estimands, responder rates, and adverse-event tables that determine how a drug is actually judged are still pending.

The earlier Chinese Phase 2 study, presented at the American Diabetes Association Scientific Sessions and published as an abstract in Diabetes, enrolled 250 non-diabetic Chinese adults with a BMI ≥28 kg/m² or 24–28 kg/m² with an obesity-related comorbidity, and reported meaningful weight reduction alongside improvements in cardiac risk factors.

CX11 Phase 2 Results in the United States

Corxel's U.S. Phase 2 trial (NCT07011797) reported top-line results in July 2026. It was a multicenter, double-blind, placebo-controlled study in 246 U.S. adults with obesity (BMI ≥30) or overweight (BMI 27–30) with at least one weight-related comorbidity, randomized 1:1:1:1:1 across five arms for 36 weeks:

CX11 120 mg once daily
CX11 160 mg once daily
CX11 200 mg once daily (slow titration)
CX11 200 mg once daily (fast titration)
Placebo

The trial met all primary endpoints for weight loss and safety, with up to 11.5% weight reduction at 36 weeks. Corxel reported that weight loss continued at a consistent rate through the end of the study with no evidence of a slowing trajectory — meaning the curve had not yet reached its plateau when the trial ended. Since Phase 3 obesity trials typically run 68–72 weeks, a still-descending curve at 36 weeks is the single most encouraging signal in the dataset.

Tolerability: The Most Interesting Number

Gastrointestinal side effects are the reason a large share of people stop GLP-1 therapy, and they have been the persistent weakness of high-dose oral small molecules. CX11's reported rates in the U.S. Phase 2:

Adverse event	Rate across CX11 arms
Nausea	33–34%
Vomiting	12–16%
Diarrhea	4–12%
Constipation	2–12%
Discontinuation due to GI events	5.0% overall

Events were characterized as generally mild to moderate, with no severe cases reported. Corxel also reported no hepatic safety signal across more than 1,500 participants studied to date — a meaningful note for this class, since liver enzyme elevations ended the development of an earlier oral small-molecule GLP-1 candidate.

A 5% discontinuation rate from GI events is low for the class. For context, the ATTAIN-1 Phase 3 trial of orforglipron reported treatment discontinuation from adverse events of roughly 10% at the 36 mg dose. Cross-trial comparisons are not evidence — different populations, titration schedules, and reporting conventions make them unreliable — but the direction is worth watching in Phase 3.

For anyone managing these symptoms on any GLP-1 drug, our guides to nausea management and constipation cover the practical strategies.

How CX11 Compares to Other Oral GLP-1 Drugs

The oral GLP-1 field has become crowded quickly. Here is where the leading candidates stand:

Drug	Developer	Type	Best reported weight loss	Duration	Stage
CX11 / VCT220	Corxel / Vincentage	Small molecule	−12.4%	52 weeks (Ph3, China)	China NDA planned; global Ph3 planned
Orforglipron	Eli Lilly	Small molecule	−12.4%	72 weeks (Ph3)	Regulatory submissions underway
Aleniglipron	Structure Therapeutics	Small molecule	−11.3% placebo-adjusted	36 weeks (Ph2b)	Phase 3 planned
Oral semaglutide 50 mg	Novo Nordisk	Peptide	−15.1%	68 weeks (Ph3)	Approved as an oral obesity treatment

Evidence: "Orforglipron, an oral small-molecule GLP-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity as compared with placebo." — ATTAIN-1 Trial. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2511774

Two caveats keep this table honest. First, CX11's 52-week figure and orforglipron's 72-week figure are not measured at the same point on the weight-loss curve; a shorter trial can flatter a drug whose curve is still falling. Second, the Chinese Phase 3 enrolled at BMI thresholds calibrated for East Asian populations (≥28 kg/m² for obesity rather than ≥30), and baseline body weight strongly influences percentage weight loss. The U.S. Phase 3 program will be the fair test.

Against Injectables

Injectable therapy still sets the benchmark. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean weight reduction of 14.9% at 68 weeks.

Evidence: "The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183

Tirzepatide sits higher still. The head-to-head SURMOUNT-5 trial gave tirzepatide a 20.2% mean reduction against semaglutide's 13.7% over 72 weeks.

Evidence: "Treatment with tirzepatide was superior to treatment with semaglutide with respect to percent change in body weight at week 72." — SURMOUNT-5 Trial. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2416394

CX11 does not compete on maximum efficacy. It competes on access. Roughly a quarter of people who could benefit from GLP-1 therapy decline it because of needles, and manufacturing capacity for injectable peptides has repeatedly constrained supply. A small-molecule tablet is cheaper to manufacture at scale, ships without a cold chain, and removes the injection barrier — a 12% weight loss that someone will actually take outperforms a 20% weight loss they refuse to start.

What Happens Next

Corxel has said it will discuss pivotal global Phase 3 design with the FDA and EMA and aims to begin enrollment in early 2027. Vincentage is pursuing a Chinese NDA on the strength of the completed Phase 3.

Realistic expectations for anyone tracking this drug:

CX11 is not available by prescription anywhere. It is investigational in every market, including China, until an NDA is approved.
No U.S. approval before 2029 at the earliest. A pivotal program starting in 2027 runs 68–72 weeks, followed by data analysis and regulatory review.
Peer-reviewed publication is the next real milestone. Every efficacy number cited from the Phase 3 and U.S. Phase 2 trials is currently a company press release. Top-line announcements omit the details that later reshape a drug's profile.
Compounded or gray-market "CX11" is not a real product. Any seller offering it is selling something else. The same warning applies to compounded semaglutide sourced outside regulated pharmacies.

Key Takeaways

CX11 (VCT220) is a credible entrant in the oral GLP-1 class rather than a breakthrough. Its Chinese Phase 3 delivered 12.4% mean weight loss over 52 weeks, its U.S. Phase 2 delivered up to 11.5% over 36 weeks with a curve that had not flattened, and its 5% GI-related discontinuation rate is at the favorable end of what this class has reported.

What separates it from the pack is less the efficacy than the logistics: no food or water restrictions, no refrigeration, no needle, and small-molecule manufacturing economics. If the global Phase 3 reproduces the Chinese result in a Western population at Western BMI thresholds, CX11 becomes a serious option for the large group of people who will take a pill and will not take an injection.

Until then it belongs on a watch list, not a treatment plan. If you are considering GLP-1 therapy now, the approved options have years of outcome data behind them — and that conversation belongs with your physician.

References

743-P: Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity. Diabetes. 2025;74(Supplement_1):743-P. DOI: 10.2337/db25-743-P
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2511774
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04476-6
Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10403):705–719. DOI: 10.1016/S0140-6736(23)01185-6
Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2416394

Note: Phase 3 (China) and Phase 2 (U.S.) efficacy and safety figures for CX11/VCT220 are drawn from Corxel Pharmaceuticals and Vincentage Pharma top-line announcements and have not yet been published in a peer-reviewed journal. They should be treated as preliminary.

Last updated: 2026-07-29 Medical review: Dr. James Chen, MD, PhD, FACE